NEW
HAVEN, Conn., Jan. 2, 2024
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced
that Vlad Coric, M.D., Chairman and Chief Executive Officer,
will present at the 42nd Annual J.P. Morgan Healthcare
Conference at The Westin St. Francis Hotel in San Francisco,
California, on Monday,
January 8, 2024 at 8:15 am (PT).
A slide deck of the presentation will be available on the
Investors section of the Biohaven website
at www.biohaven.com.
About Biohaven
Biohaven is a global clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of life-changing therapies to treat a broad
range of rare and common diseases. Biohaven's experienced
management team brings with it a track record of delivering new
drug approvals for products for diseases such as migraine,
depression, bipolar and schizophrenia. The company is advancing a
pipeline of therapies for diseases, many of which have limited or
no treatment options, leveraging its proven drug development
capabilities and proprietary platforms, including Kv7 ion channel
modulation for epilepsy and neuronal hyperexcitability, glutamate
modulation for obsessive-compulsive disorder and spinocerebellar
ataxia, myostatin inhibition for neuromuscular diseases and
metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for
neuroinflammatory disorders. Biohaven's portfolio of early- and
late-stage product candidates also includes discovery research
programs focused on TRPM3 channel activation for neuropathic pain,
CD-38 antibody recruiting, bispecific molecules for multiple
myeloma, antibody drug conjugates (ADCs), and targeted
extracellular protein degradation platform technology (MoDE™) with
potential application in neurological disorders, cancer, and
autoimmune diseases.
Forward-looking Statements
This news release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The use of certain words,
including "continue", "plan", "will", "believe", "may", "expect",
"anticipate" and similar expressions, is intended to identify
forward-looking statements. Investors are cautioned that any
forward-looking statements, including statements regarding the
future development, timing and potential marketing approval and
commercialization of development candidates, are not guarantees of
future performance or results and involve substantial risks and
uncertainties. Actual results, developments and events may differ
materially from those in the forward-looking statements as a result
of various factors including: the expected timing, commencement and
outcomes of Biohaven's planned and ongoing clinical trials; the
timing of planned interactions and filings with the FDA; the timing
and outcome of expected regulatory filings; complying with
applicable U.S. regulatory requirements; the potential
commercialization of Biohaven's product candidates; the potential
for Biohaven's product candidates to be first in class therapies;
and the effectiveness and safety of Biohaven's product candidates.
Additional important factors to be considered in connection with
forward-looking statements are described in Biohaven's filings with
the Securities and Exchange Commission, including within the
sections titled "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations". The
forward-looking statements are made as of the date of this news
release, and Biohaven does not undertake any obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer
Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
201-248-0741
Media Contact:
Mike
Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biohaven-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302024199.html
SOURCE Biohaven Ltd.